Children undergoing chemotherapy often face permanent hearing loss as a result of the toxicity of these treatments. The Children’s Cause for Cancer Advocacy is organizing a Patient Focused Drug Development meeting with the FDA in September in the hopes of getting the agency to put greater consideration into the harmful effects these drugs can have and what it means for patients to lose their hearing. We spoke to Nawal Ouzren, CEO of Sensorion, which will participate in the FDA meeting and is developing a treatment for sudden hearing loss that may be able to help these patients. We spoke to Ouzren about the problem of hearing loss for children receiving chemotherapy, why regulators and others may dismiss it as an unfortunate price to pay for a life-saving treatment, and how Sensorion’s experimental drug may help prevent these children from going deaf.